Bavarian Nordic (BAVA.CO)
-Copenhagen 68.50 
0.50(0.72%) 10:59AM EDT
| Prev Close: | 69.00 |
|---|
| Open: | 69.00 |
|---|
| Bid: | 68.00 |
|---|
| Ask: | 68.50 |
|---|
| 1y Target Est: | 111.25 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 68.00 - 69.50 |
|---|
| 52wk Range: | 42.50 - 78.00 |
|---|
| Volume: | 30,091 |
|---|
| Avg Vol (3m): | 125,444 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in DKK.
Headlines
- Q1 2013 Bavarian Nordic A/S Earnings Release - Time Not SuppliedCCBN(Thu, May 16)
- Bavarian Nordic Reports First Quarter 2013 ResultsGlobeNewswire(Thu, May 16)
- Bavarian Nordic - Interim Financial Report for the Period 1 January to 31 March 2013Thomson Reuters ONE(Thu, May 16)
- Bavarian Nordic to Host First Quarter 2013 Results Conference CallThomson Reuters ONE(Wed, May 8)
- Bavarian Nordic Wins $228 Million U.S. Smallpox Vaccine Awardat Bloomberg(Tue, Apr 16)
- Bavarian Nordic Receives Contract Valued Up to USD 228 Million From the U.S. Government Securing Continued Production and Deliveries of IMVAMUN(r) Smallpox VaccineGlobeNewswire(Tue, Apr 16)
- Bavarian Nordic Receives Contract Valued up to USD 228 Million from the U.S. Government Securing Continued Production and Deliveries of IMVAMUNE® Smallpox VaccineThomson Reuters ONE(Tue, Apr 16)
- Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Phase 3 TrialGlobeNewswire(Mon, Apr 8)
- Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Phase 3 TrialThomson Reuters ONE(Mon, Apr 8)
- Full Year 2012 Bavarian Nordic A/S Earnings Release - Time Not SuppliedCCBN(Tue, Mar 12)
- Bavarian Nordic Announces 2012 Full Year ResultsGlobeNewswire(Tue, Mar 12)
- Bavarian Nordic Announces 2012 Full Year ResultsThomson Reuters ONE(Tue, Mar 12)
- Bavarian Nordic to Host Full Year 2012 Conference CallThomson Reuters ONE(Wed, Mar 6)
- Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense ProgramsGlobeNewswire(Tue, Mar 5)
- Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense ProgramsThomson Reuters ONE(Tue, Mar 5)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-10)
: | N/A |
|---|
| Quarterly EPS Est
(Dec-10)
: | N/A |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forBAVA.CO.